HRP20150254T1 - Postupak dobivanja 4-oksokinolinskog spoja - Google Patents

Postupak dobivanja 4-oksokinolinskog spoja Download PDF

Info

Publication number
HRP20150254T1
HRP20150254T1 HRP20150254TT HRP20150254T HRP20150254T1 HR P20150254 T1 HRP20150254 T1 HR P20150254T1 HR P20150254T T HRP20150254T T HR P20150254TT HR P20150254 T HRP20150254 T HR P20150254T HR P20150254 T1 HRP20150254 T1 HR P20150254T1
Authority
HR
Croatia
Prior art keywords
compound
image
formula
alkyl group
salt
Prior art date
Application number
HRP20150254TT
Other languages
English (en)
Inventor
Koji Matsuda
Koji Ando
Shigeji Ohki
Jun-Ichi Hoshi
Takahiro Yamasaki
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of HRP20150254T1 publication Critical patent/HRP20150254T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/353—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/64—Acyl halides
    • C07C57/72—Acyl halides containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/64—Acyl halides
    • C07C57/76—Acyl halides containing halogen outside the carbonyl halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C67/32—Decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (36)

1. Spoj, naznačen time što je prikazan formulom (2′): [image] , gdje je R atom fluora ili skupina metoksi, a R400 je atom vodika ili C1-C4 alkilna skupina, ili njegova sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R skupina metoksi, ili njegova sol.
3. Upotreba spoja prikazanog formulom (8-1): [image] , gdje je X100 atom halogena, naznačena time što je spoj prikazan formulom (8-1) namijenjen dobivanju spoja prikazanog formulom (2′): [image] , gdje je R atom fluora ili skupina metoksi, a R400 je atom vodika ili C1-C4 alkilna skupina, ili njegove soli.
4. Upotreba u skladu s patentnim zahtjevom 3, naznačena time što se sastoji u upotrebi spoja prikazanog formulom (8-1): [image] i spoja prikazanog formulom (2-1): [image] , gdje je R atom fluora ili skupina metoksi, R300 je C1-C4 alkilna skupina, a X200 je atom halogena, u prisutnosti atoma metala M1, u dobivanju spoja prikazanog formulom (2′).
5. Upotreba spoja prikazanog formulom (2′): [image] , gdje je R atom fluora ili skupina metoksi, a R400 je atom vodika ili C1-C4 alkilna skupina, ili njegove soli, naznačena time što je spoj namijenjen dobivanju spoja (10): [image] , ili njegove soli.
6. Upotreba u skladu s patentnim zahtjevom 5, naznačena time što se dodatno sastoji u upotrebi spoja prikazanog formulom (8-1): [image] , gdje je X100 atom halogena, i spoja prikazanog formulom (2-1): [image] , gdje je R atom fluora ili skupina metoksi, R300 je C1-C4 alkilna skupina, a X200 je atom halogena.
7. Upotreba spoja prikazanog formulom (2-2): [image] , gdje je R atom fluora ili skupina metoksi, a R300 je C1-C4 alkilna skupina, spoja prikazanog formulom (2-3): [image] , gdje je R atom fluora ili skupina metoksi, ili njegove soli, spoja prikazanog formulom (3): [image] , gdje je R atom fluora ili skupina metoksi, spoja prikazanog formulom (4): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegove soli, spoja prikazanog formulom (5): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, i spoja prikazanog formulom (6): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, naznačena time što su navedeni spojevi namijenjeni dobivanju spoja (10): [image] , ili njegove soli.
8. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što je spoj (2-2) spoj prikazan formulom (2-2-A): [image] , gdje je R300 C1-C4 alkilna skupina; spoj (2-3) je spoj (2-3-A): [image] , ili njegova sol; spoj (3) je spoj (3-A): [image] ; spoj (4) je spoj prikazan formulom (4-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol; spoj (5) je spoj prikazan formulom (5-A): [image] , gdje je R100 C1-C4 alkilna skupina; spoj (6) je spoj prikazan formulom (6-A): [image] , gdje je R100 C1-C4 alkilna skupina; te što se dodatno sastoji u upotrebi spoja prikazanog formulom (7): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil, i spoja prikazanog formulom (9): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil.
9. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što je spoj (2-2) spoj prikazan formulom (2-2-B): [image] , gdje je R300 C1-C4 alkilna skupina; spoj (2-3) je spoj (2-3-B): [image] , ili njegova sol; spoj (3) je spoj (3-B): [image] ; spoj (4) je spoj prikazan formulom (4-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol; spoj (5) je spoj prikazan formulom (5-B): [image] , gdje je R100 C1-C4 alkilna skupina; spoj (6) je spoj prikazan formulom (6-B): [image] , gdje je R100 C1-C4 alkilna skupina; te što se dodatno sastoji u upotrebi spoja prikazanog formulom (8): [image] , gdje je R100 C1-C4 alkilna skupina.
10. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što se dodatno sastoji u upotrebi spoja prikazanog formulom (1): [image] , gdje je R atom fluora ili skupina metoksi, ili njegove soli, spoja prikazanog formulom (2): [image] , gdje je R atom fluora ili skupina metoksi, a X200 je atom halogena, ili njegove soli, i spoja prikazanog formulom (2-1): [image] , gdje je R atom fluora ili skupina metoksi, R300 je C1-C4 alkilna skupina, a X200 je atom halogena.
11. Upotreba u skladu s patentnim zahtjevom 10, naznačena time što je spoj (1) spoj (1-A): [image] , ili njegova sol; spoj (2) je spoj prikazan formulom (2-A): [image] , gdje je X200 atom halogena, ili njegova sol; spoj (2-1) je spoj prikazan formulom (2-1-A): [image] , gdje je R300 C1-C4 alkilna skupina, a X200 je atom halogena; spoj (2-2) je spoj prikazan formulom (2-2-A): [image] , gdje je R300 C1-C4 alkilna skupina; spoj (2-3) je spoj (2-3-A): [image] , ili njegova sol; spoj (3) je spoj (3-A): [image] ; spoj (4) je spoj prikazan formulom (4-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol; spoj (5) je spoj prikazan formulom (5-A): [image] , gdje je R100 C1-C4 alkilna skupina; spoj (6) je spoj prikazan formulom (6-A): [image] , gdje je R100 C1-C4 alkilna skupina; te što se dodatno sastoji u upotrebi spoja prikazanog formulom (7): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil, i spoja prikazanog formulom (9): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil.
12. Upotreba u skladu s patentnim zahtjevom 10, naznačena time što je spoj (1) spoj (1-B): [image] , ili njegova sol; spoj (2) je spoj prikazan formulom (2-B): [image] , gdje je X200 atom halogena, ili njegova sol; spoj (2-1) je spoj prikazan formulom (2-1-B): [image] , gdje je R300 C1-C4 alkilna skupina, a X200 je atom halogena; spoj (2-2) je spoj prikazan formulom (2-2-B): [image] , gdje je R300 C1-C4 alkilna skupina; spoj (2-3) je spoj (2-3-B): [image] , ili njegova sol; spoj (3) je spoj (3-B): [image] ; spoj (4) je spoj prikazan formulom (4-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol; spoj (5) je spoj prikazan formulom (5-B): [image] , gdje je R100 C1-C4 alkilna skupina; spoj (6) je spoj prikazan formulom (6-B): [image] , gdje je R100 C1-C4 alkilna skupina; te što se dodatno sastoji u upotrebi spoja prikazanog formulom (8): [image] , gdje je R100 C1-C4 alkilna skupina.
13. Postupak dobivanja spoja prikazanog formulom (2′): [image] , gdje je R atom fluora ili skupina metoksi, a R400 je atom vodika ili C1-C4 alkilna skupina, ili njegove soli, naznačen time što se sastoji u reakciji spoja prikazanog formulom (8-1): [image] , gdje je X100 atom halogena, sa spojem prikazanim formulom (2-1): [image] , gdje je R atom fluora ili skupina metoksi, R300 je C1-C4 alkilna skupina, a X200 je atom halogena, u prisutnosti atoma metala M1.
14. Postupak dobivanja spoja (10): [image] , ili njegove soli, naznačen time što se sastoji u koraku dobivanja spoja (2-3-A): [image] , ili njegove soli, iz spoja prikazanog formulom (2-2-A): [image] , gdje je R300 C1-C4 alkilna skupina; koraku dobivanja spoja (3-A): [image] , iz gore spomenutog spoja (2-3-A), ili njegove soli; koraku dobivanja spoja prikazanog formulom (4-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegove soli, iz gore spomenutog spoja (3-A); koraku dobivanja spoja prikazanog formulom (5-A): [image] , gdje je R100 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (4-A), ili njegove soli; koraku dobivanja spoja prikazanog formulom (6-A): [image] , gdje je R100 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (5-A); koraku dobivanja spoja prikazanog formulom (7): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil, iz navedenog spoja prikazanog formulom (6-A); koraku dobivanja spoja prikazanog formulom (9): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil, iz navedenog spoja prikazanog formulom (7); i koraku dobivanja gore spomenutog spoja (10), ili njegove soli, iz navedenog spoja prikazanog formulom (9).
15. Postupak dobivanja u skladu s patentnim zahtjevom 14, naznačen time što se dodatno sastoji u koraku dobivanja spoja prikazanog formulom (2-A): [image] , gdje je X200 atom halogena, ili njegove soli, iz spoja (1-A): [image] , ili njegove soli; koraku dobivanja spoja prikazanog formulom (2-1-A): [image] , gdje je R300 C1-C4 alkilna skupina, a X200 je atom halogena, iz navedenog spoja prikazanog formulom (2-A), ili njegove soli; i koraku dobivanja spoja prikazanog formulom (2-2-A): [image] , gdje je R300 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (2-1-A).
16. Postupak dobivanja spoja (10): [image] , ili njegove soli, naznačen time što se sastoji u koraku dobivanja spoja (2-3-B): [image] , ili njegove soli, iz spoja prikazanog formulom (2-2-B): [image] , gdje je R300 C1-C4 alkilna skupina; koraku dobivanja spoja (3-B): [image] , iz gore spomenutog spoja (2-3-B), ili njegove soli; koraku dobivanja spoja prikazanog formulom (4-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegove soli, iz gore spomenutog spoja (3-B); koraku dobivanja spoja prikazanog formulom (5-B): [image] , gdje je R100 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (4-B), ili njegove soli; koraku dobivanja spoja prikazanog formulom (6-B): [image] , gdje je R100 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (5-B); koraku dobivanja spoja prikazanog formulom (8): [image] , gdje je R100 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (6-B); i koraku dobivanja gore spomenutog spoja (10), ili njegove soli, iz navedenog spoja prikazanog formulom (8).
17. Postupak dobivanja u skladu s patentnim zahtjevom 16, naznačen time što se dodatno sastoji u koraku dobivanja spoja prikazanog formulom (2-B): [image] , gdje je X200 atom halogena, ili njegove soli, iz spoja (1-B): [image] , ili njegove soli; koraku dobivanja spoja prikazanog formulom (2-1-B): [image] , gdje je R300 C1-C4 alkilna skupina, a X200 je atom halogena, iz navedenog spoja prikazanog formulom (2-B); i koraku dobivanja spoja prikazanog formulom (2-2-B): [image] , gdje je R300 C1-C4 alkilna skupina, iz navedenog spoja prikazanog formulom (2-1-B).
18. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je prikazan formulom (2-3): [image] , ili njegova sol.
19. Spoj u skladu s patentnim zahtjevom 18, naznačen time što je prikazan formulom (2-3-A): [image] , ili njegova sol.
20. Spoj, naznačen time što je prikazan formulom (3): [image] , gdje je R atom fluora ili skupina metoksi.
21. Spoj, naznačen time što je prikazan formulom (4): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegova sol.
22. Spoj, naznačen time što je prikazan formulom (4-1): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegova sol.
23. Spoj, naznačen time što je prikazan formulom (4-2-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol.
24. Upotreba spoja prikazanog formulom (4-1): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegove soli, naznačena time što je spoj formule (4-1) namijenjen dobivanju spoja prikazanog formulom (4): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegova sol.
25. Upotreba spoja prikazanog formulom (4-2-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegove soli, naznačena time što je spoj formule (4-2-B) namijenjen dobivanju spoja prikazanog formulom (4-B): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol.
26. Upotreba u skladu s patentnim zahtjevom 24, naznačena time što se dodatno sastoji u upotrebi spoja prikazanog formulom (3): [image] , gdje je R atom fluora ili skupina metoksi.
27. Upotreba u skladu s patentnim zahtjevom 25, naznačena time što se dodatno sastoji u upotrebi spoja (3-B): [image] .
28. Spoj, naznačen time što je prikazan formulom (5): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina.
29. Spoj, naznačen time što je prikazan formulom (6): [image] , gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina.
30. Spoj, naznačen time što je prikazan formulom (7): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil.
31. Spoj, naznačen time što je prikazan formulom (9): [image] , gdje je R100 C1-C4 alkilna skupina, a R200 je zaštitna skupina za hidroksil.
32. Spoj, naznačen time što je prikazan formulom (8): [image] , gdje je R100 C1-C4 alkilna skupina.
33. Spoj u skladu s patentnim zahtjevom 21, naznačen time što je prikazan formulom (4-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol.
34. Spoj u skladu s patentnim zahtjevom 28, naznačen time što je prikazan formulom (5-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol.
35. Spoj u skladu s patentnim zahtjevom 29, naznačen time što je prikazan formulom (6-A): [image] , gdje je R100 C1-C4 alkilna skupina, ili njegova sol.
36. Postupak dobivanja spoja (10): [image] , ili njegove soli, naznačen time što se spoj (10) dobiva iz spoja prikazanog formulom (8): [image] , gdje je R100 C1-C4 alkilna skupina.
HRP20150254TT 2006-03-06 2015-03-06 Postupak dobivanja 4-oksokinolinskog spoja HRP20150254T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006060277 2006-03-06
JP2006060298 2006-03-06
PCT/JP2007/054348 WO2007102512A1 (ja) 2006-03-06 2007-03-06 ４－オキソキノリン化合物の製造方法
EP07737895.8A EP1992607B9 (en) 2006-03-06 2007-03-06 Method for producing 4-oxoquinoline compound

Publications (1)

Publication Number Publication Date
HRP20150254T1 true HRP20150254T1 (hr) 2015-04-10

Family

ID=38474939

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150254TT HRP20150254T1 (hr) 2006-03-06 2015-03-06 Postupak dobivanja 4-oksokinolinskog spoja

Country Status (20)

Country Link
US (4) US8383819B2 (hr)
EP (1) EP1992607B9 (hr)
JP (2) JP4669040B2 (hr)
KR (1) KR101023635B1 (hr)
AP (1) AP2914A (hr)
AU (1) AU2007223260C1 (hr)
BR (1) BRPI0708685B8 (hr)
CA (1) CA2645119C (hr)
EA (1) EA017861B9 (hr)
ES (1) ES2531190T3 (hr)
HK (1) HK1125357A1 (hr)
HR (1) HRP20150254T1 (hr)
IL (1) IL193772A (hr)
IN (1) IN2014CN00613A (hr)
MX (1) MX2008011457A (hr)
NO (1) NO20084179L (hr)
NZ (1) NZ570706A (hr)
PL (1) PL1992607T3 (hr)
RS (1) RS54047B1 (hr)
WO (1) WO2007102512A1 (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443048T1 (de) 2002-11-20 2009-10-15 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
JP4669040B2 (ja) 2006-03-06 2011-04-13 日本たばこ産業株式会社 ４−オキソキノリン化合物の製造方法
SG174787A1 (en) 2006-09-12 2011-10-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
SG11201500812QA (en) 2012-08-03 2015-04-29 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
CZ304983B6 (cs) * 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304984B6 (cs) * 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
PL2822954T3 (pl) 2012-12-21 2016-09-30 Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie
EP2938185B1 (en) 2012-12-26 2020-04-29 Société des Produits Nestlé S.A. Low density coated animal litter compositions
SI3252058T1 (sl) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV
NO2865735T3 (hr) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (hr) 2014-06-20 2018-06-23
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
NZ735575A (en) 2015-04-02 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3364752B1 (en) 2015-10-23 2022-07-06 Société des Produits Nestlé S.A. Low density pet litters and methods of making and using such pet litters
KR102662644B1 (ko) * 2019-09-24 2024-04-30 아심켐 래보러토리즈 (톈진) 컴퍼니, 리미티드 벤질 아연 할라이드 및 그 유도체의 연속 제조 방법
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772A (hr) 1971-08-11 1973-04-09
DE3501247A1 (de) 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
US5563138A (en) 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
EP0319906A3 (en) 1987-12-11 1990-05-02 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them
US4920120A (en) 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
DE3934082A1 (de) 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE4015299A1 (de) 1990-05-12 1991-11-14 Bayer Ag Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
CA2187429A1 (en) * 1994-04-28 1995-11-09 Junya Ohmori N-(3-pyrrolidinyl)benzamide derivative
AU683569B2 (en) 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
EP0892801B1 (en) 1996-04-12 2002-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Acridone-derived compounds useful as antineoplastic and antiretroviral agents
US6287550B1 (en) 1996-12-17 2001-09-11 The Procter & Gamble Company Animal care system and litter with reduced malodor impression
US5989451A (en) * 1997-02-07 1999-11-23 Queen's University At Kingston Compounds and methods for doping liquid crystal hosts
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
KR20010013377A (ko) 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JPH1184556A (ja) 1997-09-08 1999-03-26 Konica Corp ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
GB9807903D0 (en) 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
IL155677A0 (en) 2000-12-14 2003-11-23 Procter & Gamble Cyclization process step in the making of quinolones and naphthyridines
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
DE60229364D1 (de) 2001-03-01 2008-11-27 Shionogi & Co Stickstoffhaltige heteroarylverbindungen mit hiv-integrase inhibierender wirkung
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
ATE443048T1 (de) 2002-11-20 2009-10-15 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
JP4360872B2 (ja) 2003-09-16 2009-11-11 株式会社リコー 定着ローラ温度制御方法、定着装置及び画像形成装置
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4506347B2 (ja) 2004-08-17 2010-07-21 日本電気株式会社 通信端末の遠隔制御方法およびシステム
JP2006060298A (ja) 2004-08-17 2006-03-02 Canon Inc ファクシミリ装置
JP4669040B2 (ja) 2006-03-06 2011-04-13 日本たばこ産業株式会社 ４−オキソキノリン化合物の製造方法
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
JP4826772B2 (ja) 2006-08-11 2011-11-30 横河電機株式会社 機器管理システム
SG174787A1 (en) * 2006-09-12 2011-10-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2009089263A2 (en) 2008-01-07 2009-07-16 Ardea Biosciences Inc. Novel compositions and methods of use

Also Published As

Publication number Publication date
JP4669040B2 (ja) 2011-04-13
EP1992607A4 (en) 2010-12-29
EA017861B9 (ru) 2014-05-30
US8383819B2 (en) 2013-02-26
JPWO2007102512A1 (ja) 2009-07-23
ES2531190T9 (es) 2015-09-03
AU2007223260C1 (en) 2011-02-03
EA017861B1 (ru) 2013-03-29
HK1125357A1 (en) 2009-08-07
NZ570706A (en) 2010-08-27
IL193772A0 (en) 2009-08-03
AU2007223260A1 (en) 2007-09-13
CA2645119C (en) 2012-01-24
BRPI0708685B1 (pt) 2021-04-06
BRPI0708685A2 (pt) 2011-06-07
PL1992607T3 (pl) 2015-05-29
NO20084179L (no) 2008-12-01
US20130310595A1 (en) 2013-11-21
KR20080104049A (ko) 2008-11-28
BRPI0708685B8 (pt) 2021-05-25
EP1992607B1 (en) 2014-12-31
US20150299104A1 (en) 2015-10-22
EP1992607B9 (en) 2015-07-01
AP2914A (en) 2014-05-31
JP5866087B2 (ja) 2016-02-17
ES2531190T3 (es) 2015-03-11
JP2011016842A (ja) 2011-01-27
MX2008011457A (es) 2008-09-24
EA200870321A1 (ru) 2009-02-27
EP1992607A1 (en) 2008-11-19
KR101023635B1 (ko) 2011-03-22
US20180265454A1 (en) 2018-09-20
WO2007102512A1 (ja) 2007-09-13
IN2014CN00613A (hr) 2015-08-21
AU2007223260B2 (en) 2010-09-09
US20090036684A1 (en) 2009-02-05
CA2645119A1 (en) 2007-09-13
IL193772A (en) 2012-02-29
RS54047B1 (en) 2015-10-30
AP2008004621A0 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
HRP20150254T1 (hr) Postupak dobivanja 4-oksokinolinskog spoja
EA201070072A1 (ru) ПРОИЗВОДНЫЕ 6-ЦИКЛОАМИНО-3-(ПИРИДИН-4-ИЛ)ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
RU2011101140A (ru) Пирроло[2,3-b]пиридиновые производные в качестве ингибиторов протеинкиназ
RU2018131134A (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ
FI3233863T3 (fi) Fuusioidun renkaan sisältäviä heteroaryyliyhdisteitä ja niiden käyttö trk:n estäjinä
UA99257C2 (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
JP2015509939A5 (hr)
HRP20080510T3 (hr) Postupak za priređivanje optički aktivnih derivata 2-(2-piridilmetilsulfinil)-benzimidazola putem inkluzijskog kompleksa s 1,1'-binaftalen-2,2' diolom
ATE349451T1 (de) Verfahren zur herstellung von clopidogrel
WO2009093209A3 (ru) 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2009093210A3 (ru) ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2015010741A (es) Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina.
RU2010102137A (ru) Способ получения пиразолов
MY150514A (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
JP2006527170A5 (hr)
JP2017513887A5 (hr)
JP6423936B2 (ja) 放射ヨウ素標識された３−フルオロプロピル−ＮＯＲ−β−ＣＩＴの調製
JP2012036221A5 (hr)
EA201001460A1 (ru) Тетрагидропиразоло[1,5-a]пиридопиримидины - антагонисты серотониновых 5-нтрецепторов, способы их получения и применения
JP2019534301A5 (hr)
EP1568697A4 (en) 1,3-BENZOTHIAZINONE DERIVATIVES, THEIR MANUFACTURING METHOD AND USE
HRP20120961T1 (hr) Spojevi tiazolilpirazolopirimidina kao sintetski međuprodukti i odgovarajući postupci sinteze
MX2013005179A (es) Derivado de pirazino[2,3-d]isoxazol.
JP2016509033A5 (hr)
ATE249459T1 (de) N-benzenesulfonyl-l-prolin-derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung